ASBMR 2014 Annual Meeting – Live Online!

Note: All sessions will take place live in Central Standard Time (CST)

Friday, September 12, 2014

Highlights of the ASBMR 2014 Annual Meeting

10:00 am - 11:30 am CST

This session is of interest to all health professionals, first-time meeting attendees, young investigators, individuals new to the field, nurses, clinical research study coordinators, physical therapists and those seeking guidance in navigating through the extensive ASBMR program.

Co-Chairs:

Betsy McClung, R.N., M.N., Oregon Osteoporosis Center (USA) Joan Lappe, R.N., Ph.D., Creighton University Osteoporosis Research Center (USA)

Basic Science Overview

Roland Baron, DDS, PhD, Harvard School of Medicine and of Dental Medicine (USA)

Clinical Science Overview

John Bilezikian, M.D., Columbia University College of Physicians and Surgeons (USA)

Symposium - Muscle and Bone

11:30 am - 12:45 pm CST

Co-Chairs:

Lynda Bonewald, Ph.D., University of Missouri, Kansas City (USA) Mark Hamrick, Ph.D., Georgia Health Sciences University (USA)

Cancer Metastases to Bone: Regulation of Muscle Function by the Bone Microenvironment

Theresa Guise, M.D., Indiana University (USA)

Is Mettl21c Gene Associated with Osteoporosis and Sarcopenia?

Marco Brotto, BSN, Ph.D., University of Missouri, Kansas City (USA)

Muscle, Fat and Bone in Health ABC: A Molecular Epidemiology Triangle

Tamara Harris, M.D., M.S., Intramural Research Program, National Institute on Aging (USA)

ASBMR/ECTS Clinical Debate: Biochemical Markers are of Practical Value in the Routine Management of Osteoporosis

3:00 pm - 4:00 pm CST

Co-Chairs:

Kristina Akesson, M.D., Ph.D., Skane University Hospital, Malmö (Sweden) Bente Langdahl, M.D., DMSc, Aarhus University Hospital (Denmark)

Debaters:

For the motion

William Fraser, M.D., FRCP, University of East Anglia (United Kingdom)

Against the motion

Douglas Bauer, M.D., University of California, San Francisco (USA)

Saturday, September 13, 2014

Gerald D. Aurbach Lecture - Selective Autophagy: Cleaning and Fueling at the Old Trash Can 8:00 am – 9:30 am CST

Ana Maria Cuervo, M.D., Ph.D., Albert Einstein College of Medicine (USA)

Dr. Ana Maria Cuervo is the Robert and Renee Belfer Chair for the Study of Neurodegenerative Diseases, Professor in the Departments of Developmental and Molecular Biology and of Medicine of the Albert Einstein College of Medicine and co-director of the Einstein Institute for Aging Studies.

Dr. Cuervo is considered a leader in the field of protein degradation in relation to biology of aging and has been invited to present numerous lectures including the prestigous Robert R. Konh Memorial Lecture, the NIH Director's Lecture, the Roy Walford Endowed Lecture, the Feodor Lynen Lecture and the Margaret Pittman Lecture. She has organized and chaired international conferences on protein degradation and on Aging, belongs to the editorial board of scientific journals in this topic and she is currently co-Editor-in-Chief of Aging Cell and associate editor of Autophagy. She has been the recipient of prestigious awards such as the P. Benson Award in Cell Biology, the Keith Porter Fellow in Cell Biology, the Nathan Shock Memorial Lecture Award, the Vincent Cristofalo Rising Start in Aging Award, the Bennett J. Cohen award in basic aging biology and the Marshall Horwitz Prize for excellence in research. She has also received twice the LaDonne Schulman Teaching Award. Dr. Cuervo is currently member of the NIA Scientific Council and of the NIH Council on Councils.

To Mars and Beyond – How Will We Preserve the Musculoskeletal System in Long-Term Space Flights? 11:30 am – 12:30 pm CST

Co-Chairs:

Robert Gagel, M.D., University of Texas M.D. Anderson Cancer Center (USA)
Jean Sibonga, Ph.D., Bone Discipline Lead, Johnson Space Center Bone and Mineral Laboratory (USA)

Greeting from the Astronauts Currently on the ISS

Opportunities for Space-based Research

Julie Robinson, Ph.D., Chief Scientist, International Space Station, Johnson Space Center (USA)

Challenges in Assessing Bone Loss and Fracture Risk in Space Flights

Eric Orwoll, M.D., Oregon Health and Science University (USA)

Probabilistic Fracture Risk Assessment

Jerry Myers, Ph.D., NASA John Glenn Research Center (USA)

Experience of ASBMR Investigators with Active Space-based Research Programs:

Working with NASA

Thomas Lang, Ph.D., University of California, San Francisco (USA)

Working with Industry

Mary Bouxsein, Ph.D., Beth Israel Deaconess Medical Center, Harvard Medical School (USA)

Working with NIH

Paola Divieti Pajevic, M.D., Ph.D., Massachusetts General Hospital and Harvard Medical School (USA)

Sunday, September 14, 2014

Lessons from Brittle Bone Diseases: Control of Bone Mass and Quality

8:00 am - 9:30 am CST

This activity is supported by an educational grant from Lilly

Co-Chairs:

Brendan Lee, M.D., Ph.D., Baylor College of Medicine, Howard Hughes Medical Institute (USA) Deborah Krakow, M.D., University of California, Los Angeles (USA)

Genetics of OI and Homeostatic Mechanisms in the Skeleton

Brendan Lee, M.D., Ph.D., Baylor College of Medicine, Howard Hughes Medical Institute (USA)

Collagen/Matrix Abnormalities

David Eyre, Ph.D., University of Washington (USA)

OI Treatment, A Multidisciplinary Approach

Francis Glorieux, M.D., Ph.D., Shriners Hospital for Children, McGill University (Canada)

The Clinical Diagnosis of Osteoporosis: Report of an NBHA Working Group

11:30 am - 12:00 pm CST

An NBHA Working Group, composed of representatives of ASBMR, NOF, AAOS and the liaison to NBHA from the CDC, was charged with the task of expanding the criteria by which a diagnosis of osteoporosis can be made in postmenopausal women and men age 50 and older in the US. Ethel Siris, M.D., Columbia University College of Physicians and Surgeons, will present the report detailing the process and the conclusions.

International ONJ Task Force - 2014 Consensus on Diagnosis and Management

12:00 pm - 12:30 pm CST

This session will present an update on the 2014 Consensus on Diagnosis and Management by the International ONJ Task Force. The presentations will cover diagnosis and pathophysiology, incidence and prevention strategies and staging and advances in management.

Symposium - Heterotopic Ossification

4:30 pm - 5:45 pm CST

This activity is supported by an educational grant from Merck & Co., Inc.

Co-Chairs:

Edward Hsiao, M.D., Ph.D., University of California, San Francisco (USA) Harald Jueppner, M.D., Massachusetts General Hospital (USA)

Heterotopic Ossification in Combat Wounds

Jonathan Forsberg, M.D., Walter Reed National Military Medical Center (USA)

Activation of Hedgehog Signaling by GNAS Inactivation Causes Ectopic Osteoblast Differentiation in POH

Yingzi Yang, Ph.D., National Institutes of Health (USA)

Pharmacological Prevention of Heterotopic Ossification

Maurizio Pacifici, Ph.D., Children's Hospital of Philadelphia (USA)

Monday, September 15, 2014

ASBMR Task Force Reports

11:30 am - 12:30 pm CST

This session will feature presentations from the chairs of the ASBMR Task Force on Managing Osteoporosis Patients after Long-term Bisphosphonate Treatment and the ASBMR-NOF Task Force on Goals for Osteoporosis Treatment.

ASBMR Task Force on Managing Osteoporosis Patients after Long-term Bisphosphonate Treatment Chairs:

Robert Adler, M.D., McGuire VA Medical Center and Virginia Commonwealth University Ghada El-Hajj Fuleihan, M.D., MPH, American University of Beirut Medical Center

ASBMR-NOF Task Force on Goals for Osteoporosis Treatment

Chair:

Steven Cummings, M.D., FACP, University of California, San Francisco (USA)

Plenary Symposium - Next-Gen Therapies

2:30 pm - 4:00 pm CST

This activity is supported by an educational grant from Lilly

Co-Chairs:

Dennis Black, Ph.D., University of California, San Francisco (USA) Bente Langdahl, M.D., DMSc, Aarhus University Hospital (Denmark)

Overview of Current Treatments

Dennis Black, Ph.D., University of California, San Francisco (USA)

Nitric Oxide Donors: A Novel Way to Increase Bone Mass, Density and Strength

Sophie Jamal, M.D., Ph.D., University of Toronto (Canada)

PTH Treatment of Hypoparathyroidism

Lars Rejnmark, M.D., Ph.D., Aarhus University Hospital (Denmark)

Anti-Sclerostin Therapy

E. Michael Lewiecki, M.D., FACP, FACE, University of New Mexico School of Medicine (USA)